Clinical Research Papers:

Diagnosis and treatment pattern among rural and urban breast cancer patients in Southwest China from 2005 to 2009

Zuxiang Peng, Jia Wei, Xuesong Lu, Hong Zheng, Xiaorong Zhong, Weiguo Gao, Yunqin Chen and Jing Jing _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:78168-78179. https://doi.org/10.18632/oncotarget.11375

Metrics: PDF 1935 views  |   HTML 1907 views  |   ?  


Zuxiang Peng1,*, Jia Wei2,*, Xuesong Lu2,*, Hong Zheng1, Xiaorong Zhong1, Weiguo Gao2, Yunqin Chen2 and Jing Jing1

1 Department of Thyroid and Breast Surgery, Laboratory of Molecular Diagnosis of Cancer, State Key Laboratory of Biotherapy, National Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China

2 AstraZeneca R&D Information China, Zhangjiang Hi-Tech Park, Shanghai, China

* These authors have contributed equally to this work

Correspondence to:

Jing Jing, email:

Keywords: breast cancer; epidemiology; survival; treatment; real-world study

Received: May 20, 2016 Accepted: August 13, 2016 Published: August 18, 2016


The incidence of all cancers in China is generally higher in urban areas; however, the mortality risk for affected patients is considerably higher in rural areas. We present a subanalysis investigating the differences in patient and disease characteristics, treatment patterns, and outcomes between rural and urban patients who were diagnosed with breast cancer at West China Hospital between 2005–2009. Baseline patient and disease characteristics were recorded, and patients were followed up for a minimum of 3 years, or until death. For this subanalysis, patients were stratified by their residential status (rural or urban). Of the 2252 patients in the cohort, 76.3% were from urban areas and 22.1% were from rural areas. Significant differences were observed in the prevalence of luminal A and human epidermal growth factor receptor 2-positive breast cancers among rural and urban patients. Estrogen receptor (ER)-positive patients were less likely to receive anti-ER therapy if they were from rural areas compared with urban areas; the use of aromatase inhibitors was also significantly lower for rural patients than urban patients. Univariate, multivariate, and Kaplan–Meier analyses all demonstrated that overall survival and progression-free survival were significantly lower for rural patients than urban patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11375